{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:23:01Z","timestamp":1790284981426,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31871319"],"award-info":[{"award-number":["31871319"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82125028"],"award-info":[{"award-number":["82125028"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91953114"],"award-info":[{"award-number":["91953114"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303108"],"award-info":[{"award-number":["82303108"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U22A20320"],"award-info":[{"award-number":["U22A20320"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["JCYJ20230807091159001"],"award-info":[{"award-number":["JCYJ20230807091159001"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["20720190145"],"award-info":[{"award-number":["20720190145"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["20720220003"],"award-info":[{"award-number":["20720220003"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["H3K4me3"],"award-info":[{"award-number":["H3K4me3"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["GSE267724"],"award-info":[{"award-number":["GSE267724"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["GSE267725"],"award-info":[{"award-number":["GSE267725"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["GSE60272"],"award-info":[{"award-number":["GSE60272"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["GSE23701"],"award-info":[{"award-number":["GSE23701"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["H3K9me3"],"award-info":[{"award-number":["H3K9me3"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["GSE62229"],"award-info":[{"award-number":["GSE62229"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2020YFA0803600"],"award-info":[{"award-number":["2020YFA0803600"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2020YFA0112300"],"award-info":[{"award-number":["2020YFA0112300"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Science Bulletin"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.scib.2025.09.044","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T07:24:47Z","timestamp":1759303487000},"page":"3822-3839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Nuclear receptor ESRRA promotes ER\u03b1-positive breast cancer through dual action on super enhancers and promoters to regulate gene transcriptional programs"],"prefix":"10.1016","volume":"70","author":[{"given":"Zao-Zao","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Sheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Ling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Xuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.scib.2025.09.044_b0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.scib.2025.09.044_b0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas N","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.scib.2025.09.044_b0015","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.scib.2025.09.044_b0020","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMc2101282","article-title":"Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer","volume":"384","author":"Burstein","year":"2021","journal-title":"Reply N Engl J Med"},{"key":"10.1016\/j.scib.2025.09.044_b0025","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III Emerald trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.scib.2025.09.044_b0030","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S1470-2045(19)30026-9","article-title":"Immunotherapy and targeted therapy combinations in metastatic breast cancer","volume":"20","author":"Esteva","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.scib.2025.09.044_b0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (impassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.scib.2025.09.044_b0040","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.scib.2025.09.044_b0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.42107","article-title":"Pembrolizumab plus chemotherapy followed by pembrolizumab in patients with early triple-negative breast cancer: a secondary analysis of a randomized clinical trial","volume":"6","author":"Takahashi","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.scib.2025.09.044_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2023.01.001","article-title":"Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer\u2014a single-arm phase II trial (Neoimmunoboost, AGO-B-041)","volume":"184","author":"Fasching","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.scib.2025.09.044_b0055","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","article-title":"Super-enhancers in the control of cell identity and disease","volume":"155","author":"Hnisz","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.scib.2025.09.044_b0060","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","article-title":"Master transcription factors and mediator establish super-enhancers at key cell identity genes","volume":"153","author":"Whyte","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.scib.2025.09.044_b0065","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1093\/nar\/gkac778","article-title":"Super-enhancer-controlled positive feedback loop BRD4\/ER\u03b1-RET-ER\u03b1 promotes ER\u03b1-positive breast cancer","volume":"50","author":"Zheng","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.scib.2025.09.044_b0070","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1124\/pharmrev.121.000436","article-title":"International union of basic and clinical pharmacology CXIII: nuclear receptor superfamily\u2014update 2023","volume":"75","author":"Burris","year":"2023","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.scib.2025.09.044_b0075","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1210\/er.2008-0017","article-title":"Transcriptional control of energy homeostasis by the estrogen-related receptors","volume":"29","author":"Gigu\u00e8re","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.scib.2025.09.044_b0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12943-022-01547-3","article-title":"Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR\/SRc\/ErK\/SP1 signaling-mediated ERR\u03b1 re-expression","volume":"21","author":"Pan","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.scib.2025.09.044_b0085","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-022-01372-7","article-title":"Targeting ERR\u03b1 promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation","volume":"15","author":"Seo","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.scib.2025.09.044_b0090","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.3390\/cancers14163885","article-title":"Estrogen related receptor alpha (ERR\u03b1) a bridge between metabolism and adrenocortical cancer progression","volume":"14","author":"Avena","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.scib.2025.09.044_b0095","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13046-021-02211-2","article-title":"Lipid reprogramming induced by the TFEB-ERR\u03b1 axis enhanced membrane fluidity to promote EC progression","volume":"41","author":"Mao","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.scib.2025.09.044_b0100","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1210\/jc.2005-1990","article-title":"Function of estrogen-related receptor alpha in human endometrial cancer","volume":"91","author":"Watanabe","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.scib.2025.09.044_b0105","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.7150\/ijbs.57623","article-title":"ESRRA promotes gastric cancer development by regulating the CDC25C\/CDK1\/CyclinB1 pathway via DSN1","volume":"17","author":"Li","year":"2021","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.scib.2025.09.044_b0110","doi-asserted-by":"crossref","first-page":"6153","DOI":"10.1158\/0008-5472.CAN-19-1231","article-title":"PGC1\u03b1 suppresses prostate cancer cell invasion through ERR\u03b1 transcriptional control","volume":"79","author":"Valcarcel-Jimenez","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.scib.2025.09.044_b0115","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.7150\/thno.35589","article-title":"Nuclear receptor err\u03b1 contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis","volume":"10","author":"Xu","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.scib.2025.09.044_b0120","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.3390\/cancers14194879","article-title":"PGC-1\u03b2 and ERR\u03b1 promote glutamine metabolism and colorectal cancer survival via transcriptional upregulation of PCK2","volume":"14","author":"Frodyma","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.scib.2025.09.044_b0125","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13046-018-0862-8","article-title":"ERR\u03b1 suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells","volume":"37","author":"Zhou","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.scib.2025.09.044_b0130","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.ejca.2005.04.008","article-title":"Oestrogen receptor-related receptor alpha (ERR\u03b1) and oestrogen receptors (ER\u03b1 and ER\u03b2) exhibit different gene expression in human colorectal tumour progression","volume":"41","author":"Cavallini","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.scib.2025.09.044_b0135","article-title":"Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer","volume":"3","author":"Dings","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.scib.2025.09.044_b0140","article-title":"ERR\u03b1 regulates the growth of triple-negative breast cancer cells via S6K1-dependent mechanism","volume":"2","author":"Berman","year":"2017","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.scib.2025.09.044_b0145","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1007\/s12015-023-10605-2","article-title":"Estrogen-related receptor alpha (ERR\u03b1) promotes cancer stem cell-like characteristics in breast cancer","volume":"19","author":"Muduli","year":"2023","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.scib.2025.09.044_b0150","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1021\/acs.est.1c03446","article-title":"Benzotriazole ultraviolet stabilizers promote breast cancer cell proliferation via activating estrogen-related receptors \u03b1 and \u03b3 at human-relevant levels","volume":"56","author":"He","year":"2022","journal-title":"Environ Sci Technol"},{"key":"10.1016\/j.scib.2025.09.044_b0155","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.canlet.2021.01.007","article-title":"FBXl10 promotes ERR\u03b1 protein stability and proliferation of breast cancer cells by enhancing the mono-ubiquitylation of ERR\u03b1","volume":"502","author":"Yang","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.scib.2025.09.044_b0160","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3390\/cells9081819","article-title":"Cholesterol and mevalonate: two metabolites involved in breast cancer progression and drug resistance through the ERR\u03b1 pathway","volume":"9","author":"Brindisi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.scib.2025.09.044_b0165","doi-asserted-by":"crossref","first-page":"12156","DOI":"10.1038\/ncomms12156","article-title":"ERR\u03b1 mediates metabolic adaptations driving lapatinib resistance in breast cancer","volume":"7","author":"Deblois","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.scib.2025.09.044_b0170","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.celrep.2016.03.026","article-title":"ERR\u03b1-regulated lactate metabolism contributes to resistance to targeted therapies in breast cancer","volume":"15","author":"Park","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.scib.2025.09.044_b0175","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/s41388-018-0579-3","article-title":"ERR\u03b1 promotes breast cancer cell dissemination to bone by increasing rank expression in primary breast tumors","volume":"38","author":"Vargas","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.scib.2025.09.044_b0180","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1158\/0008-5472.CAN-19-3584","article-title":"ERR\u03b1 expression in bone metastases leads to an exacerbated antitumor immune response","volume":"80","author":"Bouchet","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.scib.2025.09.044_b0185","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1158\/0008-5472.CAN-11-1431","article-title":"Dual function of ERR\u03b1 in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin","volume":"71","author":"Fradet","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.scib.2025.09.044_b0190","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1016\/j.celrep.2019.05.066","article-title":"Inhibition of ERR\u03b1 prevents mitochondrial pyruvate uptake exposing NADPH-generating pathways as targetable vulnerabilities in breast cancer","volume":"27","author":"Park","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.scib.2025.09.044_b0195","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/onc.2012.221","article-title":"Regulation of glycolysis and the Warburg effect by estrogen-related receptors","volume":"32","author":"Cai","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.scib.2025.09.044_b0200","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S1043-2760(02)00592-1","article-title":"To err in the estrogen pathway","volume":"13","author":"Giguere","year":"2002","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.scib.2025.09.044_b0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006347","article-title":"ERR\u03b1 negatively regulates type I interferon induction by inhibiting TBK1-IRF3 interaction","volume":"13","author":"He","year":"2017","journal-title":"Plos Pathog"},{"key":"10.1016\/j.scib.2025.09.044_b0210","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.immuni.2015.07.003","article-title":"Orphan nuclear receptor ERR\u03b1 controls macrophage metabolic signaling and A20 expression to negatively regulate TLR-induced inflammation","volume":"43","author":"Yuk","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.scib.2025.09.044_b0215","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/2159-8290.CD-22-0244","article-title":"Discovery of targets for immune-metabolic antitumor drugs identifies estrogen-related receptor alpha","volume":"13","author":"Sahu","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.scib.2025.09.044_b0220","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.scib.2025.09.044_b0225","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/annonc\/mdx179","article-title":"Pattern recognition receptors: immune targets to enhance cancer immunotherapy","volume":"28","author":"Shekarian","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.scib.2025.09.044_b0230","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-065X.2008.00737.x","article-title":"Innate immunity to virus infection","volume":"227","author":"Takeuchi","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.scib.2025.09.044_b0235","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.immuni.2008.07.009","article-title":"Structural mechanism of RNA recognition by the RIG-I-like receptors","volume":"29","author":"Yoneyama","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.scib.2025.09.044_b0240","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ni1087","article-title":"The RNA helicase Rig-I has an essential function in double-stranded RNA-induced innate antiviral responses","volume":"5","author":"Yoneyama","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.scib.2025.09.044_b0245","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.4049\/jimmunol.175.5.2851","article-title":"Shared and unique functions of the DExD\/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity","volume":"175","author":"Yoneyama","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.scib.2025.09.044_b0250","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1073\/pnas.0606699104","article-title":"Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2","volume":"104","author":"Saito","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.scib.2025.09.044_b0255","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.immuni.2011.05.003","article-title":"Immune signaling by RIG-I-like receptors","volume":"34","author":"Loo","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.scib.2025.09.044_b0260","first-page":"17","article-title":"Induction of IRF-3 and IRF-7 phosphorylation following activation of the RIG-I pathway","volume":"52","author":"Paz","year":"2006","journal-title":"Cell Mol Biol"},{"key":"10.1016\/j.scib.2025.09.044_b0265","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2013.07.011","article-title":"Turning tumors into vaccines: co-opting the innate immune system","volume":"39","author":"van den Boorn","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.scib.2025.09.044_b0270","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cell.2010.03.029","article-title":"Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity","volume":"141","author":"Zeng","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.scib.2025.09.044_b0275","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1021\/jm049334f","article-title":"Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related receptor \u03b1","volume":"47","author":"Busch","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.scib.2025.09.044_b0280","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.scib.2025.09.044_b0285","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1135","article-title":"Egfr-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo","volume":"9","author":"Xia","year":"2020","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.scib.2025.09.044_b0290","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11060-021-03703-z","article-title":"Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR","volume":"152","author":"Vaidya","year":"2021","journal-title":"J Neuro-Oncol"},{"key":"10.1016\/j.scib.2025.09.044_b0295","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1074\/jbc.M705937200","article-title":"Estrogen induces estrogen-related receptor alpha gene expression and chromatin structural changes in estrogen receptor (ER)-positive and ER-negative breast cancer cells","volume":"283","author":"Hu","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.scib.2025.09.044_b0300","article-title":"DDX58 deficiency leads to triple negative breast cancer chemotherapy resistance by inhibiting Type I IFN-mediated signalling apoptosis","volume":"14","author":"Cao","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.scib.2025.09.044_b0305","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1038\/s41467-023-39607-x","article-title":"Ultrasound-responsive low-dose doxorubicin liposomes trigger mitochondrial DNA release and activate cGAS-STING-mediated antitumour immunity","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.scib.2025.09.044_b0310","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg3207","article-title":"Transcription factors: from enhancer binding to developmental control","volume":"13","author":"Spitz","year":"2012","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.scib.2025.09.044_b0315","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.stem.2012.08.002","article-title":"Esrrb is a direct Nanog target gene that can substitute for Nanog function in pluripotent cells","volume":"11","author":"Festuccia","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.scib.2025.09.044_b0320","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1021\/jm049334f","article-title":"Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related receptor alpha","volume":"47","author":"Busch","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.scib.2025.09.044_b0325","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1073\/pnas.0401420101","article-title":"Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligand","volume":"101","author":"Willy","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.scib.2025.09.044_b0330","doi-asserted-by":"crossref","first-page":"28328","DOI":"10.1074\/jbc.M704295200","article-title":"Potentiation of ICI182,780 (Fulvestrant)-induced estrogen receptor-alpha degradation by the estrogen receptor-related receptor-alpha inverse agonist XCT790","volume":"282","author":"Lanvin","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.scib.2025.09.044_b0335","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41419-025-07499-y","article-title":"High glucose levels promote glycolysis and cholesterol synthesis via erralpha and suppress the autophagy-lysosomal pathway in endometrial cancer","volume":"16","author":"Mao","year":"2025","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.scib.2025.09.044_b0340","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd0724","article-title":"Network-based screen in iPSC-derived cells reveals therapeutic candidate for heart valve disease","volume":"371","author":"Theodoris","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.scib.2025.09.044_b0345","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41467-024-44726-0","article-title":"Enhancing aortic valve drug delivery with PAR2-targeting magnetic nano-cargoes for calcification alleviation","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.scib.2025.09.044_b0350","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1021\/bi500737n","article-title":"The estrogen-related receptor alpha inverse agonist XCT 790 is a nanomolar mitochondrial uncoupler","volume":"53","author":"Eskiocak","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.scib.2025.09.044_b0355","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1126\/science.277.5328.965","article-title":"AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer","volume":"277","author":"Anzick","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.scib.2025.09.044_b0360","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.canlet.2020.09.017","article-title":"Elevated GCN5 expression confers tamoxifen resistance by upregulating AIB1 expression in ER-positive breast cancer","volume":"495","author":"Oh","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.scib.2025.09.044_b0365","article-title":"Brd4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer","volume":"119","author":"Liu","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.scib.2025.09.044_b0370","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2426179122","article-title":"Estrogen-related receptors regulate innate and adaptive muscle mitochondrial energetics through cooperative and distinct actions","volume":"122","author":"Fan","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.scib.2025.09.044_b0375","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3389\/fonc.2018.00322","article-title":"Plasticity of type I interferon-mediated responses in cancer therapy: from anti-tumor immunity to resistance","volume":"8","author":"Budhwani","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.scib.2025.09.044_b0380","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1127623","article-title":"CGAS-dependent proinflammatory and immune homeostatic effects of the microtubule-targeting agent paclitaxel","volume":"14","author":"Serpico","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.scib.2025.09.044_b0385","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.celrep.2014.08.055","article-title":"Control of embryonic stem cell identity by BRD4-dependent transcriptional elongation of super-enhancer-associated pluripotency genes","volume":"9","author":"Di Micco","year":"2014","journal-title":"Cell Rep"}],"container-title":["Science Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927325009843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095927325009843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:05:46Z","timestamp":1773180346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095927325009843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":77,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2095927325009843"],"URL":"https:\/\/doi.org\/10.1016\/j.scib.2025.09.044","relation":{},"ISSN":["2095-9273"],"issn-type":[{"value":"2095-9273","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nuclear receptor ESRRA promotes ER\u03b1-positive breast cancer through dual action on super enhancers and promoters to regulate gene transcriptional programs","name":"articletitle","label":"Article Title"},{"value":"Science Bulletin","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.scib.2025.09.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. and Science China Press.","name":"copyright","label":"Copyright"}]}}